Volume 1.16 | May 7

Prostate Cell News 1.16, May 7, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Genome Breakthrough Allows Scientists to Identify and Profile Tumor Cells from Very Small Samples
Researchers have developed a powerful new technique for analyzing the genome of single tumor cells. The breakthrough allows them to study in fine detail the biology of how tumors develop and has the potential to help doctors identify dangerous tumor cells from small samples such as fine-needle biopsies from the prostate or a non-invasive lesion in the breast. [EurekAlert! Press Release]

Watch Procedure Now  
Optimized Enzymes and Protocols for
Prostate Tissue Dissociation

by STEMCELL Technologies


Zoledronic Acid Prevents Fractures in Prostate Cancer With Bone Metastases
Monthly infusions of the bisphosphonate zoledronic acid significantly reduce the risk for bone fractures in men with prostate cancer and malignant bone metastases. [Press release from Medscape discussing research presented at the European Association of Urology 25th Annual Congress]

Prostate Cancer Test a Flop in Study
A technique that urologists had hoped would make it possible to distinguish men with prostate cancer who need treatment from those who would only need watchful waiting didn’t work well, researchers report. [Press release from Medline Plus discussing online prepublication in Journal of Clinical Oncology]

Watch Procedure Now  

Culture and Characterize Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies




Molecular Origin of Plasma Membrane Citrate Transporter in Human Prostate Epithelial Cells
The prostate is a highly specialized mammalian organ that produces and releases large amounts of citrate. However, the citrate release mechanism is not known. Here, researchers present the results of molecular cloning of a citrate transporter from human normal prostate epithelial PNT2-C2 cells shown previously to express such a mechanism. [EMBO Rep]

ENMD-1198, A New Analogue of 2-Methoxyestradiol, Displays Both Antiangiogenic and Vascular-Disrupting Properties
In this in vitro study, researchers investigated the antivascular properties of ENMD-1198, a new anticancer drug currently in clinical trials. [Mol Cancer Ther]

Role of the Protein Tyrosine Phosphatase SHP-1 in Interleukin-6 Regulation of Prostate Cancer Cells
SHP-1 suppresses growth and increases apoptosis in both LNCaP and LNCaP-IL6+ cells, which suggests that SHP-1 could be a therapeutic target in prostate cancer, even when there is an IL-6-related growth advantage. [Prostate]

Armoring CRAds with p21/Waf-1 shRNAs: The Next Generation of Oncolytic Adenoviruses
In this study, researchers investigated the importance of the cyclin-dependent kinase inhibitor p21/Waf-1, on viral replication and tumor growth. [Cancer Gene Ther]

Targeting MMP-9, uPAR, and Cathepsin B Inhibits Invasion, Migration and Activates Apoptosis in Prostate Cancer Cells
In this study, the therapeutic potential of siRNA-mediated targeting of matrix metalloproteinase-9 (MMP-9), urokinase plasminogen activator receptor (uPAR), and cathepsin B in prostate cancer was carried out using single and bi-cistronic siRNA-expressing constructs. [Cancer Gene Ther]

Xeno-Oestrogens and Phyto-Oestrogens are Alternative Ligands for the Androgen Receptor
This study aimed to use a computerized docking approach to examine the interactions between the human androgen receptor and phyto-oestrogens (genistein, daidzein, and flavone) and xeno-oestrogens [bisphenol A, 4-nonylphenol, dichlorodiphenyl trichloroethane (DDT), diethylstilbestrol (DES)]. [Asian J Androl]

Prostate-Specific Antigen Kinetics During Follow-Up Are an Unreliable Trigger for Intervention in a Prostate Cancer Surveillance Program
The purpose of this study was to assess the predictive ability of prostate-specific antigen velocity and doubling time for biopsy progression and adverse pathology at prostatectomy among men with low-risk prostate cancer enrolled on an active-surveillance program. [J Clin Oncol]

A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [-2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness
The study objective was to characterize the clinical utility of serum prostate-specific antigen (PSA) isoform, [-2]proPSA, for prostate cancer detection and assess its association with aggressive disease. [Cancer Epidemiol Biomarkers Prev]


Details of New Wellcome Trust Investigator Awards Announced
The Wellcome Trust announces further details of its Investigator Awards, a major new scheme to support world-class researchers to tackle ambitious research questions about health and disease. [Wellcome Trust Press Release]

Synta Pharmaceuticals Reports First Quarter 2010 Financial Results
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, reported financial results for the quarter ended March 31, 2010. [Synta Pharmaceuticals Corp. Press Release]

BioSante Pharmaceuticals Announces Reinitiation of Prostate Cancer Vaccine Development
BioSante Pharmaceuticals, Inc. announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. [BioSante Pharmaceuticals, Inc. Press Release]

Mistakes, Little Oversight Cited for Philadelphia VA Prostate Cancer Treatment
When doctors from the University of Pennsylvania performed prostate cancer procedures at the Philadelphia VA Medical Center, they made dozens of mistakes over six years, and investigators could find no evidence that anyone was providing oversight, concluded a report issued by the Department of Veterans Affairs Inspector General’s Office. [The Philadelphia Inquirer]

U.S. Reviews Diabetes, Heart Risk with Prostate Drugs
The U.S. Food and Drug Administration is examining if certain hormone treatments for men with prostate cancer pose a greater risk of diabetes or heart problems than other therapies. [Reuters]

Insiders at Dendreon Cash In on Drug Approval
Dendreon Corp. President and Chief Executive Mitchell Gold sold more than $28 million of company stock in the hours after the U.S. Food and Drug Administration approved the cancer treatment Provenge late last week. [The Wall Street Journal]


Science Panel Cuts Authorization Levels for Three COMPETES Agencies
The House of Representatives Science and Technology Committee today scaled back proposed funding levels for three key science agencies as part of its reauthorization of the America COMPETES Act. [The House of Representatives Science and Technology Committee, United States]

Commission to Boost Research and Innovation by Making it Easier to Apply for and Manage European Union Grants
The European Commission has unveiled a plan to simplify the procedures for taking part in European Union-funded research projects. [European Research, Innovation and Science Commision, European Union]

Final Opportunity to Attend a 2010 NIH Regional Seminar on Program Funding & Grants Administration: Register Now for Portland, OR (June 24-25, 2010) (NOT-OD-10-092) [National Institutes of Health, United States]

Frequently Asked Questions (FAQ) for: Centers of Research Translation (CORT) (P50) RFA-AR-11-002 { NOT-AR-10-035) [National Institutes of Health, United States]

Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Predoctoral Fellows in PharmD/PhD Programs (F31) (PA-10-178) [National Institutes of Health, United States]

Extension of Expiration Date for PA-07-277, PA-06-367, and PA-06-368: Research on Ethical Issues in Human Subjects Research (NOT-OD-10-086) [National Institutes of Health, United States]

Guidance for Industry: Requalification Method for Reentry of Blood Donors Deferred Because of Reactive Test Results for Antibody to Hepatitis B Core Antigen (Anti-HBc); Availability (Docket No. FDA-2008-D-0263) [Food and Drug Administration, United States]

Emerging Infectious Diseases: Evaluation to Implementation for Transfusion and Transplantation Safety and Quantitative Risk Assessment: Blood Safety and Availability; Public Workshops (Docket No. FDA-2010-N-0001) [Food and Drug Administration, United States]


American Urological Association (AUA) 2010 Annual Meeting
May 29-June 3, 2010
San Francisco, United States

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

21st Meeting of the European Association for Cancer Research (EACR) 
June 26-29, 2010
Oslo, Norway

United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA)
August 23-27, 2010
Toronto, Canada

28th World Congress of Endourology and SWL
September 1-4, 2010
Chicago, United States

35th European Society for Medical Oncology (ESMO) Congress
October 8–12, 2010
Milan, Italy

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Sr. Product Support and Training Specialist (CardianBCT)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us